Wells Fargo kept USD 10 target for Voyager Therapeutics stock

Published on 10/18/2026 at 12:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue fell to USD 3.17 million from USD 5.20 million. Voyager Therapeutics stock had a EUR 103.95 million market value on October 16, 2026.

Analyst view and operating scale

Wells Fargo kept a USD 10.00 price target on October 2, 2026.
Second-quarter revenue fell to USD 3.17 million from USD 5.20 million.
Voyager Therapeutics is scheduled to report quarterly results on November 9, 2026.

VYGR, US92915B1061, Illustration mit AI erstellt.

Voyager Therapeutics (US92915B1061) entered the latest investor discussion with Wells Fargo maintaining a USD 10.00 price target on October 2, 2026, according to Markets Insider. The target contrasts with the company's latest operating figures, which show a smaller revenue base and continuing losses.

Target stays above recent results

Markets Insider reported that Wells Fargo maintained its Buy rating and USD 10.00 target in a report dated October 2, 2026. The same report said Voyager generated USD 3.17 million of revenue in the quarter ended June 30, 2026, compared with USD 5.20 million in the prior-year quarter, while GAAP net loss narrowed to USD 24.47 million from USD 33.38 million.

The revenue comparison is the key counterweight to the analyst view. MarketBeat said the quarter produced a USD 0.40 GAAP loss per share against a USD 0.48 consensus loss, but revenue missed the USD 4.52 million consensus estimate.

Three events shape the timeline

On July 13, 2026, Voyager said a single intravenous dose of VY1706 was well tolerated in a six-month GLP toxicology study, with an Alzheimer disease clinical trial expected in the second half of 2026, according to Voyager Therapeutics. On August 6, 2026, the company reported second-quarter revenue of USD 3.17 million. On October 2, 2026, Wells Fargo maintained its USD 10.00 target.

What does the next date mean?

The next scheduled reporting date is November 9, 2026, according to the dated calendar entry on wallstreetONLINE. That report will give investors a new revenue period and an update on the VY1706 development timeline.

Market value and pipeline remain linked

Voyager Therapeutics had a market capitalization of EUR 103.95 million on Tradegate on October 16, 2026. The same dated market page listed a 52-week range of EUR 1.69 to EUR 4.76 and identified Nasdaq as the primary exchange. The company describes its TRACER platform as a basis for genetic medicines aimed at neurological diseases, including Alzheimer disease, Parkinson disease and amyotrophic lateral sclerosis.

The further course of trading is shown by the continuously updated real-time quote of Voyager Therapeutics stock.